Opinion|Videos|September 12, 2024
Advancing CML Management Towards an Ideal Patient Journey
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
- What excites you most about the potential advancements in CML management that may be on the horizon in the next 5 to 10 years?
- How do you envision the CML patient experience being transformed compared to today? What would an "ideal" CML journey look like for patients and their loved ones? What would be your top recommendations if you were to advise the broader healthcare system on how to better support CML patients and caregivers?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5